Ipsen S.A. (FRA:I7G)

Market Cap	8.56B
Revenue (ttm)	3.76B
Net Income (ttm)	447.90M
Shares Out	n/a
EPS (ttm)	5.37
PE Ratio	19.10
Forward PE	9.64
Dividend	1.40 (1.22%)
Ex-Dividend Date	Jun 4, 2025

Volume	n/a
Average Volume	10
Open	115.00
Previous Close	112.50
Day's Range	115.00 - 115.00
52-Week Range	90.20 - 125.00
Beta	n/a
RSI	72.79
Earnings Date	Jul 31, 2025

About Intra-Cellular Therapies

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1929
• Employees: 5,358
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I7G

Financial Performance

In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.